Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for Hard-to-Treat cancers

NCT ID NCT06974110

Recruiting now Disease control Sponsor: MOMA Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-stage study tests a new oral drug, MOMA-341, alone or with other treatments, in people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goal is to check safety and find the best dose. About 132 adults whose cancer has not responded to standard therapies will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm gastric cancer gastric neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR COLORECTAL CANCER DMMR CANCER ENDOMETRIAL CANCER GASTRIC CANCER METASTATIC SOLID TUMOR MSI-H CANCER

Contacts and locations

Locations

  • Investigative Site #101

    RECRUITING

    San Diego, California, 92037, United States

  • Investigative Site #110

    RECRUITING

    St Louis, Missouri, 63108, United States

  • Investigative Site #119

    RECRUITING

    Perth, Western Australia, 6009, Australia

  • Investigative Site #120

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Investigative Site #121

    RECRUITING

    Portland, Oregon, 97239, United States

  • Investigative Site #122

    RECRUITING

    Sydney, New South Wales, 2031, Australia

  • Investigative Site #123

    RECRUITING

    Westmead, New South Wales, 2145, Australia

  • Investigative Site #124

    COMPLETED

    Woolloongabba, Queensland, 4102, Australia

  • Investigative Site #125

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Investigative Site #126

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • Investigative Site #127

    COMPLETED

    Dallas, Texas, 75230, United States

  • Investigative Site #128

    RECRUITING

    Tampa, Florida, 33612, United States

  • Investigative Site #129

    RECRUITING

    Houston, Texas, 77030, United States

  • Investigative Site #131

    RECRUITING

    Raleigh, North Carolina, 27710, United States

  • Investigative Site #132

    RECRUITING

    Phoenix, Arizona, 85054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.